Investment/financing deals cooling in 24Q1. It's better not to spend too much time on Biotech that located in China and only for China market.Decoupling deadline with WuXi is set.This is far from over
What is covered in the Full Insight:
Industry Viewpoints
Domestic Innovative Drugs
US BIOSECURE Act
Market Review
Risk Disclosure
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.